Načítá se...
Copper Chelation Inhibits BRAF(V600E)-driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors
MEK1/2 and BRAF(V600E) inhibitors are used to treat BRAF(V600E)-positive melanoma, with other cancers under evaluation. Genetic perturbation of copper import or pharmacological reduction of copper with the clinical copper chelator TTM inhibits MEK1/2 kinase activity and reduces BRAF(V600E)-driven tu...
Uloženo v:
| Vydáno v: | Cancer Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5690876/ https://ncbi.nlm.nih.gov/pubmed/28986383 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1190 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|